Imricor Medical Systems has secured A$60 million through a placement to fund its US commercial rollout, regulatory approvals, and clinical programs, boosting its cash reserves to nearly A$103 million.
- A$60 million placement at A$1.85 per share
- Funds to launch NorthStar in US pediatric and adult markets
- Advances regulatory approvals for full Electrophysiology platform
- Supports clinical trials including VISABL-VT and Pulsed Field Ablation
- Cash reserves expected to reach approximately A$102.9 million post-raise
Capital Raise Strengthens Imricor's Growth War Chest
Imricor Medical Systems (ASX:IMR) has completed a A$60 million placement priced at A$1.85 per share, representing a 6.3% discount to its last traded price before a trading halt. The raise, supported by new and existing institutional investors, will boost Imricor’s cash reserves to an estimated A$102.9 million, positioning the company with ample liquidity to advance its commercial and clinical ambitions.
This capital injection arrives as Imricor prepares to scale its US market presence, particularly with the launch of its NorthStar Mapping System, now cleared by the FDA for adult use and currently under review for pediatric expansion. The company plans to target pediatric hospitals alongside adult centres equipped with cardiovascular magnetic resonance (CMR) facilities, aiming to broaden adoption of its interventional MR platform beyond cardiology.
Funding Clinical Trials and Regulatory Milestones
Proceeds from the placement will also accelerate regulatory approvals for Imricor’s full Electrophysiology (EP) platform in the US, a critical step in expanding the product suite available to clinicians. The company intends to complete the VISABL-VT clinical trial in Europe and initiate a ventricular tachycardia (VT) trial in the US in 2027, further underpinning its clinical validation efforts.
Additionally, Imricor is advancing its Pulsed Field Ablation (PFA) technology targeting atrial fibrillation, a promising area that could expand the clinical applications of MR-guided ablation procedures. The raise will fund development and commercial rollout of these technologies, alongside expanding product offerings such as biopsy catheters and interventional tools.
Expanding Geographic Reach and Product Capabilities
The company is also earmarking funds to bolster its presence in the Middle East, a region identified as a key growth market. Expansion efforts include investing in dedicated resources to support clinical and commercial activities. Imricor’s CEO Steve Wedan highlighted the company’s strong regulatory momentum and growing commercial interest, noting that the capital raise provides the financial strength to transition from momentum to scale.
Wedan emphasized that with NorthStar cleared in the US and pediatric label expansion submitted, Imricor is exceptionally well positioned to expand its installed base and continue building what it describes as the world’s leading interventional MR platform. This funding round follows a series of regulatory and clinical advancements, including recent FDA clearances and ongoing trial expansions, which have laid the groundwork for commercial growth in the US and Europe.
The placement is scheduled to settle on 7 May 2026, with new shares expected to commence trading on the ASX on 8 May. Joint lead managers Morgans Corporate, Canaccord Genuity, and Taylor Collison facilitated the transaction, which was conducted under the company’s existing placement capacity.
Imricor’s recent capital raise builds on its prior funding rounds and regulatory progress, including the US FDA clearances earlier this year and the submission for pediatric approval, reflecting a strategic push to cement its position in the growing market for MR-guided cardiac ablation technologies. The company’s cash position and planned investments signal a clear intent to accelerate commercialisation and clinical adoption across multiple regions and indications.
Given the inherent uncertainties in regulatory approvals and clinical trial outcomes, the success of Imricor’s growth strategy will hinge on timely milestones and market uptake. However, the fresh capital provides a robust runway to pursue these objectives aggressively.
Imricor’s strategy and recent funding moves can be seen alongside its earlier FDA clearance progress and cash outflow report and pediatric label expansion submission, which together frame a company gearing up for a significant commercial phase.
Bottom Line?
Imricor’s A$60 million raise equips it to push forward on multiple fronts, but execution risks around regulatory approvals and clinical trials remain key hurdles.
Questions in the middle?
- Will Imricor secure timely FDA approvals for its full Electrophysiology platform and pediatric NorthStar indication?
- How quickly can Imricor convert regulatory momentum into sustainable US commercial sales?
- What impact will the Pulsed Field Ablation development have on the company’s competitive positioning?